Trends in GLP-1 Receptor Agonist Prescribing Without an Apparent FDA-Approved Indication. (PubMed, Obesity (Silver Spring)) - Sep 23, 2026 - "GLP-1 receptor agonist prescribing without an apparent FDA-approved indication has increased rapidly and disproportionately involves socioeconomically advantaged populations, including individuals without obesity. The risk-benefit profile in these populations remains uncertain."
FDA event • Journal • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Diabetes • Dyslipidemia • Genetic Disorders • Heart Failure • Hypertension • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus
|
|
Allan B Massie; Babak J Orandi; Christine J Ren-Fielding; Dorry L Segev; Holly F Lofton; Karan R Chhabra; Leila Yan; Macey L Levan; Mara A McAdams-DeMarco; Michal A Mankowski; S Ali Husain
|